Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 15 2014 - 3:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
|
¨
Form 10-K
¨
Form 20-F
¨
Form 11-K
x
Form 10-Q
¨
Form 10-D
|
|
¨
Form N-SAR
¨
Form N-CSR
|
For
Period Ended:
June 30, 2014
¨
Transition Report on Form 10-K
¨
Transition Report on Form 20-F
¨
Transition Report on Form 11-K
¨
Transition Report on Form 10-Q
¨
Transition Report on Form N-SAR
For
the Transition Period Ended:___________________________
Read attached instruction sheet before preparing form. Please
print or type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
PART I
REGISTRANT INFORMATION
Cytocore,
Inc.
Full Name of Registrant
Former Name if Applicable
4203
SW 34
th
St.
Address of Principal Executive Office (Street and Number)
Orlando,
FL 32811
City, State and Zip Code
PART II
RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if
appropriate)
ý
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
ý
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
¨
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K,
20-F, 11-K, 10-Q, 10-D, N-SAR or N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time
period.
(Attach extra Sheets if Needed)
The Registrant was unable to timely file its Quarterly Report
on Form 10-Q for the period ended June 30, 2014 (the “Quarterly Report”) due to the fact that this Quarterly Report
represents the first periodic report of the Registrant required to include the financial statements of Medite Enterprise, Inc.,
which was acquired by the Registrant on April 3, 2014. The Registrant intends to file the Quarterly Report with the Securities
and Exchange Commission within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934,
as amended.
PART IV
OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard
to this notification.
|
Robert McCullough, Jr.
|
(407)
|
996-9631
|
(Name)
|
(Area Code)
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section
13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify
report(s).
|
x
Yes
¨
No
|
(3)
|
Is it anticipated that any significant change in results
of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
|
¨
Yes
x
No
If so, attach an explanation
of the anticipated change, both normatively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Cytocore,
Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
August 15, 2014
|
By:
|
/s/ Robert McCullough, Jr.
|
|
|
Robert McCullough, Jr.
|
|
|
Chief Financial Officer
|
INSTRUCTION: The form may be signed by an executive officer
of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed
or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other
than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with
the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
Himalaya Technologies (PK) (USOTC:HMLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Himalaya Technologies (PK) (USOTC:HMLA)
Historical Stock Chart
From Apr 2023 to Apr 2024